Order online in 2 minutes, visit a local lab same day, and get results in 1-3 days. No doctor's order needed.
Thyroid cancer is highly curable Today, with overall five-year survival rates exceeding 98% for the most common types when detected early. The curability depends on the specific histologic subtype, stage at diagnosis, and patient factors such as age and overall health. For papillary and follicular thyroid cancers, which account for over 90% of cases, complete remission is the norm. Medullary and anaplastic types pose greater challenges, but advances in targeted therapy and immunotherapy are improving outcomes even for aggressive forms.
Papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) are classified as differentiated thyroid cancers. They retain the ability to take up iodine, making radioactive iodine (RAI) therapy highly effective after thyroidectomy. Today, the standard of care includes total or near-total thyroidectomy followed by RAI ablation for intermediate- and high-risk patients. TSH suppression therapy with levothyroxine further reduces recurrence risk. For localized disease, the cure rate approaches 99%. Even with regional lymph node involvement, five-year survival remains above 95%.
Medullary thyroid cancer (MTC) arises from parafollicular C-cells and does not respond to RAI. Cure relies on complete surgical resection before metastasis. Today, routine calcitonin screening and genetic testing for RET mutations enable earlier detection. For advanced MTC, selective RET inhibitors like selpercatinib and pralsetinib have dramatically improved progression-free survival. Anaplastic thyroid cancer (ATC), while rare, remains the most aggressive. However, combination therapies with BRAF/MEK inhibitors (for BRAF V600E-mutant ATC) and checkpoint inhibitors are yielding durable responses in a subset of patients, shifting the prognosis from uniformly fatal to potentially curable in selected cases.
| Thyroid Cancer Type | Localized (Stage I–II) | Regional Spread | Distant Metastasis |
|---|---|---|---|
| Papillary | >99% | 95–98% | 70–80% |
| Follicular | >95% | 85–90% | 50–60% |
| Medullary | 90–95% | 70–80% | 30–40% |
| Anaplastic | 20–30% | <10% | <5% |
Note: Five-year relative survival rates based on SEER data and recent clinical trials. Individual outcomes vary.
Because thyroid cancer often presents as a painless neck lump, many cases are found incidentally during imaging or routine physical exams. Today, blood tests such as thyroglobulin (Tg), anti-thyroglobulin antibodies, and calcitonin are essential for monitoring after treatment. Rising Tg levels can signal recurrence months before imaging detects it. For medullary thyroid cancer, calcitonin and carcinoembryonic antigen (CEA) serve as sensitive biomarkers. Regular lab surveillance allows for early intervention, which directly improves curability. At mylabpanel.com, we offer comprehensive thyroid cancer monitoring panels that include these critical markers, enabling you and your healthcare provider to stay ahead of recurrence.
Take control of your thyroid health today. Order your thyroid cancer monitoring panel from mylabpanel.com and get reliable, fast results to support your treatment journey.
Ready to order your test?
Order online in 2 minutes and visit a local lab same day.
Find a Lab Near MeFor papillary and follicular thyroid cancers, the five-year survival rate exceeds 98% when caught early. Medullary thyroid cancer has a 90–95% survival rate for localized disease, while anaplastic thyroid cancer remains more challenging but newer therapies are improving outcomes.
Yes, recurrence is possible, especially in the first few years. Regular monitoring with thyroglobulin blood tests and neck ultrasound is standard. Most recurrences are treatable, especially if caught early.
Surgery (thyroidectomy) is the primary curative treatment for most thyroid cancers. Radioactive iodine and targeted therapies are used as adjuncts, but complete removal of the thyroid is typically required for cure.
Thyroglobulin (Tg), anti-thyroglobulin antibodies, and calcitonin (for medullary cancer) are the key markers. mylabpanel.com offers comprehensive panels for ongoing surveillance.
Affiliate disclosure: MyLabPanel may earn a commission when you book a test through links on this page, at no extra cost to you.